• An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer

  NCT07132645

  RecruitingInterventionalEarly Phase 1Updated Jul 31, 2026
• 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer

  NCT04050215

  CompletedInterventionalPhase 2Updated Sep 30, 2021
• Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

  NCT07118176

  Active, not recruitingInterventionalPhase 1Updated Jul 2, 2026
• 68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer

  NCT03831711

  CompletedInterventionalPhase 1Phase 2Updated Dec 13, 2023
• The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate Cancer

  NCT04179968

  CompletedInterventionalPhase 2Updated Mar 20, 2023
• An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors

  NCT04040088

  Active, not recruitingInterventionalEarly Phase 1Updated Mar 31, 2026

ClinicalTrials.gov ID

NCT04480619

Lead Sponsor

Advanced Imaging Projects, LLCINDUSTRY

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Phase 1Phase 2

Enrollment

25Estimated

Last Update Posted

Jul 16, 2025Actual

Start Date

Oct 30, 2025Estimated

Primary Completion Date

May 30, 2027Estimated

Completion Date

Aug 30, 2027Estimated

Official Title

Safety and Efficacy of Ga-68-IAC Positron Emission Tomography (PET/CT) for Diagnosis and Clinical Management in Metastatic Breast Cancer Patients.

Brief Summary

This is a phase I/IIa, open label, multicenter interventional study of Gallium-68 radiolabeled Integrin Adhesion Complex antagonist conjugate (Ga-68-IAC) Positron Emission Tomography (PET/CT) imaging, intended for diagnosis, and clinical management of patients with Metastatic breast cancer.

Detailed Description

This is a prospective non blinded trial, Phase I/IIa, multicenter, study in a total of up to 25 subjects with angiogenic therapy indication for breast cancer. All patients with confirmed diagnoses will undergo [18F]Fluoro-deoxyglucose (18F-FDG) PET/CT (6-12 mCi) and Ga-68-IAC PET/CT 2-5 mCi to evaluate safety, biodistribution, and response to treatment in metastatic breast cancer patients.

• Angiogenic Breast Cancer

• Ga-68-IAC

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Patients with solid tumors (either 3+ by immunohistochemistry or with evidence of gene amplification (>2.0) by fluorescence in situ hybridization (FISH))

  • At least 18 years of age
  • Able to provide informed consent.

Karnofsky score greater than 50

• Females of childbearing potential must have a negative pregnancy test at screening/baseline

• AIP-301 Ga-68 positive scan define by SUV greater than 10.

• Adequate organ function, defined as:

  1. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L.
  2. Hemoglobin (Hb) ≥9 g/dl (transfusion or use of EPO is permitted).
  3. Platelets > 100,000/mm3
  4. Creatinine ≤ 1.5 x normal value based on the Cock Gault (CG) equation.
  5. AST or ALT ≤ 2.5 x ULN (or ≤5 x ULN in case of liver metastasis)
  6. Alkaline phosphatase ≤2.5 x ULN. Alkaline phosphatase may be more than 2.5 x ULN only in the case of bone metastases, and AST and ALT less than 1.5 x ULN.
  7. Total bilirubin ≤1.5 mg/dl (higher bilirubin levels are permitted if the patient has Gilbert's syndrome).

Baseline LVEF ≥50% measured using echocardiogram or equilibrium

isotopic ventriculography (MUGA).

Exclusion Criteria:

• • Serum creatinine >3.0 mg/dL (270 μM/L)

  • Hepatic enzyme levels more than 5 times upper limit of normal.

  • Known severe allergy or hypersensitivity to IV radiographic contrast.

  • Use of any other investigational product or device within 30 days prior to dosing or known requirement for any other investigational agent prior to completion of all scheduled study assessments.

  • Patients with a body weight of 400 pounds or more or not able to enter the bore of the PET/CT scanner due to BMI, because of the compromise in image quality with CT, PET/CT and MRI that will result.

  • Inability to lie still for the entire imaging time (e.g. cough, severe arthritis, etc.).

  • Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)

  • Recognized concurrent active infection (e.g., HIV)

  • Previous Grade 3 or higher allergic reaction to Trastuzumab that resulted in discontinuation of Trastuzumab therapy. Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance.

    • Adult patients who require monitored anesthesia for PET scanning

Primary Purpose

Diagnostic

Allocation

N/A

Interventional Model

Single Group Assignment

Masking

None (Open Label)

Lead Sponsor

Advanced Imaging Projects, LLCINDUSTRY

Collaborators

All India Institute of Medical SciencesOTHER

Post Graduate Institute of Medical Education and Research, ChandigarhOTHER

University of Witwatersrand, South AfricaOTHER

US Department of Veterans AffairsFED

drcsbal@gmail.com01126546477

Mboyo-Di-Tamba.Vangu@wits.ac.za0832670004